Arthritis Advisory Committee; Notice of Meeting, 61979-61980 [06-8787]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 203 / Friday, October 20, 2006 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10078]
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Centers for Medicare &
Medicaid Services, HHS.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS), Department of Health
and Human Services, is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the Agency’s function;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
1. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Matching Grants
to States for the Operation of High Risk
Pools and Supporting Regulations at 42
CFR 148.316, 148.318, and 148.320;
Use: CMS is requiring this information
as a condition of eligibility for grants
that were authorized in the Trade Act of
2002 (Pub. L. 107–210). The information
is necessary to determine if a State
applicant meets the necessary eligibility
criteria for a grant as required by the
law. The respondents will be States that
have a high risk pool as defined in
Section 2744(c)(2) of the Public Health
Service Act. The grants will provide
matching funds to States that incur
losses in the operation of high risk
pools. High risk pools are set up by
States to provide health insurance to
individuals that cannot obtain health
insurance in the private market because
of a history of illness. Form Number:
CMS–10078 (OMB#: 0938–0887);
Frequency: Reporting—On occasion;
Affected Public: State, local, or tribal
government; Number of Respondents:
33; Total Annual Responses: 33; Total
Annual Hours: 1,320.
jlentini on PROD1PC65 with NOTICES
AGENCY:
VerDate Aug<31>2005
15:52 Oct 19, 2006
Jkt 211001
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS Web site
address at https://www.cms.hhs.gov/
PaperworkReductionActof1995, or email your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786–
1326.
Written comments and
recommendations for the proposed
information collections must be mailed
or faxed within 30 days of this notice
directly to the OMB desk officer: OMB
Human Resources and Housing Branch,
Attention: Carolyn Lovett, New
Executive Office Building, Room 10235,
Washington, DC 20503, Fax Number:
(202) 395–6974.
Dated: October 4, 2006.
Michelle Shortt,
Director, Regulations Development Group,
Office of Strategic Operations and Regulatory
Affairs.
[FR Doc. E6–17034 Filed 10–19–06; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10202]
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Centers for Medicare &
Medicaid Services, HHS.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS), Department of Health
and Human Services, is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the Agency’s function;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
AGENCY:
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
61979
1. Type of Information Collection
Request: New Collection; Title of
Information Collection: Data Collection
for Administering the Medicare Health
Improvement Survey; Use: This
beneficiary survey is to obtain
information about beneficiary behavior,
physical functioning and satisfaction
with the care management programs
data required to evaluate the Medicare
Care Management for High Cost
Beneficiaries demonstration (CMHCB).
This demonstration provides an
opportunity to test new models of care
for Medicare beneficiaries who are highcost and who have complex chronic
conditions with the goals of reducing
future costs, improving quality of care
and quality of life, and improving
beneficiary and provider satisfaction.
Form Number: CMS–10202 (OMB#:
0938–New); Frequency: Reporting—On
occasion; Affected Public: Individuals or
Households; Number of Respondents:
3633; Total Annual Responses: 3633;
Total Annual Hours: 908.
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS Web site
address at https://www.cms.hhs.gov/
PaperworkReductionActof1995, or
e-mail your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786–
1326.
Written comments and
recommendations for the proposed
information collections must be mailed
or faxed within 30 days of this notice
directly to the OMB desk officer: OMB
Human Resources and Housing Branch,
Attention: Carolyn Lovett, New
Executive Office Building, Room 10235,
Washington, DC 20503, fax number:
(202) 395–6974.
Dated: October 12, 2006.
Michelle Shortt,
Director, Regulations Development Group,
Office of Strategic Operations and Regulatory
Affairs.
[FR Doc. E6–17353 Filed 10–19–06; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Arthritis Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
E:\FR\FM\20OCN1.SGM
Notice.
20OCN1
jlentini on PROD1PC65 with NOTICES
61980
Federal Register / Vol. 71, No. 203 / Friday, October 20, 2006 / Notices
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Arthritis
Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on November 29, 2006, from 8 a.m.
to 5 p.m.
Location: Hilton Washington DC
North/Gaithersburg, The Ballrooms, 620
Perry Pkwy., Gaithersburg, MD.
Contact Person: Johanna M. Clifford,
Center for Drug Evaluation and Research
(HFD–21), Food and Drug
Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm.
1093), Rockville, MD 20857, 301–827–
7001, FAX: 301–827–6776, e-mail:
Johanna.Clifford@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512532. Please call the Information
Line for up-to-date information on this
meeting. The background material will
become available no later than the day
before the meeting and will be posted
on FDA’s Web site at https://
www.fda.gov/ohrms/dockets/ac/
acmenu.htm under the heading
‘‘Arthritis Advisory Committee.’’ (Click
on the year 2006 and scroll down to the
above named committee meeting).
Agenda: The committee will discuss
the safety and efficacy of the
nonsteriodal anti-inflammatory drug
(COX–2 inhibitor) new drug application
(NDA) 20–998/S021, CELEBREX
(celecoxib), Pfizer, Inc., for the proposed
indication of the relief of the signs and
symptoms of juvenile rheumatoid
arthritis in patients 2 years and older.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before November 15, 2006.
Oral presentations from the public will
be scheduled between approximately
11:30 a.m. and 12:30 p.m. Time allotted
for each presentation may be limited.
Those desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before
November 15, 2006.
VerDate Aug<31>2005
15:52 Oct 19, 2006
Jkt 211001
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Johanna
Clifford at least 7 days in advance of the
meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: October 13, 2006.
Randall W. Lutter,
Associate Commissioner for Policy.
[FR Doc. 06–8787 Filed 10–19–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Neurological Devices Panel of the
Medical Devices Advisory Committee;
Notice of Postponement of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug Administration
(FDA) is postponing the meeting of the
Neurological Devices Panel scheduled
for October 31, 2006. The meeting was
announced in the Federal Register of
September 22, 2006 (71 FR 55491).
FDA’s Center for Devices and
Radiological Health will further
evaluate data relevant to the topic. A
future meeting date will be announced
in the Federal Register.
Contact Person: Janet L. Scudiero,
Center for Devices and Radiological
Health (HFZ–410), Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 301–594–1184, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington, DC area), code
3014512513. Please call the Information
Line for up-to-date information on this
meeting.
Dated: October 13, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and
Planning.
[FR Doc. 06–8788 Filed 10–19–06; 8:45 am]
BILLING CODE 4160–01–S
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Circulatory System Devices Panel of
the Medical Devices Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Circulatory
System Devices Panel of the Medical
Devices Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on December 7 and 8, 2006, from
8 a.m. to 5:30 p.m.
Location: Hilton Washington DC
North/Gaithersburg, Salons A, B, and C,
620 Perry Pkwy., Gaithersburg, MD.
Contact Person: James Swink, Center
for Devices and Radiological Health
(CDRH) (HFZ–450), Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 301–443–8262,
ext. 163, or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), code 3014512625. Please call the
Information Line for up-to-date
information on this meeting.
Agenda: The committee will discuss
and make recommendations regarding
issues related to stent thrombosis in
coronary drug-eluting stents.
Background information for the topic,
including the agenda and questions for
the committee, will be available to the
public 1 business day before the
meeting on the Internet at https://
www.fda.gov/cdrh/panel (click on
Upcoming CDRH Advisory Panel/
Committee Meetings).
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before November 15, 2006.
Oral presentations from the public will
be scheduled on both days for
approximately 1 hour at the beginning
of committee deliberations and for
approximately 1 hour near the end of
the deliberations. Time allotted for each
presentation may be limited. Those
desiring to make formal oral
presentations should notify the contact
E:\FR\FM\20OCN1.SGM
20OCN1
]]>Agencies
[Federal Register Volume 71, Number 203 (Friday, October 20, 2006)]
[Notices]
[Pages 61979-61980]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-8787]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Arthritis Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
[[Page 61980]]
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Arthritis Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on November 29, 2006, from
8 a.m. to 5 p.m.
Location: Hilton Washington DC North/Gaithersburg, The Ballrooms,
620 Perry Pkwy., Gaithersburg, MD.
Contact Person: Johanna M. Clifford, Center for Drug Evaluation and
Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857,
301-827-7001, FAX: 301-827-6776, e-mail: Johanna.Clifford@fda.hhs.gov,
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 3014512532. Please call the
Information Line for up-to-date information on this meeting. The
background material will become available no later than the day before
the meeting and will be posted on FDA's Web site at https://www.fda.gov/
ohrms/dockets/ac/acmenu.htm under the heading ``Arthritis Advisory
Committee.'' (Click on the year 2006 and scroll down to the above named
committee meeting).
Agenda: The committee will discuss the safety and efficacy of the
nonsteriodal anti-inflammatory drug (COX-2 inhibitor) new drug
application (NDA) 20-998/S021, CELEBREX (celecoxib), Pfizer, Inc., for
the proposed indication of the relief of the signs and symptoms of
juvenile rheumatoid arthritis in patients 2 years and older.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
November 15, 2006. Oral presentations from the public will be scheduled
between approximately 11:30 a.m. and 12:30 p.m. Time allotted for each
presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time requested to make their presentation
on or before November 15, 2006.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Johanna Clifford at
least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: October 13, 2006.
Randall W. Lutter,
Associate Commissioner for Policy.
[FR Doc. 06-8787 Filed 10-19-06; 8:45 am]
BILLING CODE 4160-01-S
